BioCentury
ARTICLE | Company News

Hetero Drugs sales and marketing update

September 14, 2015 7:00 AM UTC

Hetero launched Maball rituximab in India to treat non-Hodgkin’s lymphoma (NHL) and chronic lymphocytic leukemia (CLL). Maball is a biosimilar of MabThera/ Rituxan rituximab from Roche (SIX:ROG; OTC...